Show simple item record

dc.contributor.authorCalifano, Raffaele
dc.contributor.authorKazarnowicz, A
dc.contributor.authorKaraseva, N
dc.contributor.authorSanchez, A
dc.contributor.authorLiu, V
dc.contributor.authorHorn, L
dc.contributor.authorQuach, C
dc.contributor.authorYu, W
dc.contributor.authorKabbinavar, F
dc.contributor.authorLam, S
dc.contributor.authorMansfield, A
dc.date.accessioned2019-03-29T14:22:30Z
dc.date.available2019-03-29T14:22:30Z
dc.date.issued2018en
dc.identifier.citationCalifano R, Ka?arnowicz A, Karaseva N, Sánchez A, Liu SV, Horn L, et al. IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC). Ann Oncol. 2018;29(suppl_10):17.en
dc.identifier.doi10.1093/anonc/mdy486en
dc.identifier.urihttp://hdl.handle.net/10541/621658
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/anonc/mdy486en
dc.titleIMpower133: patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentKing's College, London, London, United Kingdomen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record